The short version of trans-3-hexenoyl fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-04-09. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
| Property | Value | Notes |
|---|---|---|
| Drug class | Peptide hormone analog | Acts at the growth hormone-releasing hormone receptor |
| Receptor | Growth hormone-releasing hormone receptor | G protein-coupled; raises cyclic AMP in somatotrophs |
| Key mediator | Insulin-like growth factor 1 | Increases with repeated administration |
| Main studied population | Adults with HIV-associated lipodystrophy | Trials measured visceral adipose tissue by imaging |
| Route | Subcutaneous injection | Given once daily in clinical use |
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
== Structures == Both classes of aminoacyl-tRNA synthetases are multidomain proteins. In a typical scenario, an aaRS consists of a catalytic domain (where both the above reactions take place) and an anticodon binding domain (which interacts mostly with the anticodon region of the tRNA). Transfer-RNAs for different amino acids differ not only in their anticodon but also at other points, giving them slightly different overall configurations. The aminoacyl-tRNA synthetases recognize the correct tRNAs primarily through their overall configuration, not just through their anticodon. In addition, some aaRSs have additional RNA binding domains and editing domains that cleave incorrectly paired aminoacyl-tRNA molecules. The catalytic domains of all the aaRSs of a given class are found to be homologous to one another, whereas class I and class II aaRSs are unrelated to one another. The class I aaRSs feature a cytidylyltransferase-like Rossmann fold seen in proteins like glycerol-3-phosphate cytidylyltransferase, nicotinamide nucleotide adenylyltransferase and archaeal FAD synthase, whereas the class II aaRSs have a unique fold related to biotin and lipoate ligases. The alpha helical anticodon binding domain of arginyl-, glycyl- and cysteinyl-tRNA synthetases is known as the DALR domain after characteristic conserved amino acids. Aminoacyl-tRNA synthetases have been kinetically studied, showing that Mg2+ ions play an active catalytic role and therefore aaRs have a degree of magnesium dependence.
{\displaystyle {\begin{aligned}u(r)&={\frac {G}{4\mu }}\left(R_{1}^{2}-r^{2}\right)+{\frac {G}{4\mu }}\left(R_{2}^{2}-R_{1}^{2}\right){\frac {\ln(r/R_{1})}{\ln(R_{2}/R_{1})}},\\[6pt]Q&={\frac {G\pi }{8\mu }}\left[R_{2}^{4}-R_{1}^{4}-{\frac {\left(R_{2}^{2}-R_{1}^{2}\right)^{2}}{\ln(R_{2}/R_{1})}}\right].\end{aligned}}}
== Personal life == Watson met Dutch model Virginia Slaghekke, who was represented by Donald Trump's Trump Model Management, at Hole in the Wall in New York City while he was working there during his suspension in 2016, and they began dating in August 2016. Slaghekke, a neuroscience/pre-medical student at the time, later moved to Melbourne on a student exchange program to support Watson during his final AFL season. They have two children together.
Some forms of fabrication tested in outer space are fused deposition printing, which employs 3D printing methods to print using layer-by-layer filament extrusions, semi-solid and direct powder extrusion, effective for bioprinting applications and can be leveraged to process materials found in outer space (silica, magnesium silicate, and calcium phosphate), and photopolymerization, which uses light to print a resin in a layer-by-layer mechanism. These methods are not only used for drug manufacturing but also for biomaterials or medical devices that can load drugs. Finally, methods are used to conduct quality assurance, such as gas chromatography, mass spectrometry, infrared spectroscopy, nuclear magnetic resonance spectroscopy, and other such techniques to identify potential toxins in drug formulations. Advances in handheld, portable, and component miniaturization have developed spectroscopy methods to be more accessible for outer space applications. For example, Raman spectroscopy is a handheld device that can measure drug degradation and drug parameters and efficacy.
Sources: en.wikipedia.org
Alistair Barkley who goes on the run with Eddie when they are framed for Alistair's murder and the destruction of his laboratory Fred Ward as FBI Agent Leon Ford, who leads the investigation to discover the cause of the destruction of the laboratory; initially focusing on Eddie and Lily, he soon suspects the involvement of government organizations Kevin Dunn as FBI Agent Doyle, Ford's assistant in the investigation who helps Ford track down Eddie, Lily, and later, C-Systems Brian Cox as Lyman Earl Collier, Chairman of C-Systems Research who is behind the conspiracy to keep the hydrogen power plant a secret Joanna Cassidy as Maggie McDermott, an old friend of Eddie's who lives in an observatory in Wisconsin, where Eddie and Lily escape to after a warrant is issued for their arrest Chelcie Ross as FBI Agent Ed Rafferty Nicholas Rudall as Dr. Alistair Barkley, head of the project to develop energy from the water who is later suffocated Tzi Ma as Lu Chen, Project Manager on the Hydrogen Project and Dr. Barkley's right-hand man; when Barkley is killed, Dr. Chen is kidnapped and forced to work at C-Systems Krzysztof Pieczyński as Lucasz Screbneski, the scientist on the original project who is secretly working for C-Systems Eddie Bo Smith Jr. and Danny Goldring as Yusef Reed and Clancy Butler, Collier's right hand men for C-Systems Margaret Travolta as Anita Fermi, Shannon's personal assistant. In addition, Michael Shannon and Neil Flynn make appearances as a van driver and a Wisconsin State Police Trooper, respectively.
DiCaprio is agnostic. His personal life is the subject of widespread media attention, though he rarely grants interviews and is reluctant to discuss his private life. Since his 40s, DiCaprio has been the focus of various reports detailing his involvement with women aged 25 or younger, and has faced criticism for the age disparity of those relationships. In 1999, DiCaprio met Brazilian model Gisele Bündchen, whom he dated until 2005. He was romantically involved with Israeli model Bar Refaeli from 2005 to 2011. He later dated German fashion model Toni Garrn from 2013 to 2014 and later in 2017. DiCaprio was briefly romantically linked with Barbadian singer Rihanna, with the pair attending Coachella together in 2016. DiCaprio successfully sued French tabloid Oops after it made claims that DiCaprio had gotten Rihanna pregnant. DiCaprio was in a relationship with American model and actress Camila Morrone from 2017 until 2022. He has been dating Italian model Vittoria Ceretti since August 2023. DiCaprio owns houses in Los Angeles and apartments in New York City. In 2009, he bought an island, Blackadore Caye, off mainland Belize—on which he is set to open an environmentally friendly resort—and in 2014, he purchased the original Dinah Shore residence designed by architect Donald Wexler in Palm Springs, California. In 2005, DiCaprio's face was severely injured when model Aretha Wilson hit him over the head with a broken bottle at a Hollywood party. As a result, he required seventeen stitches to his face and neck.
Carpal tunnel syndrome (CTS) is the symptoms and signs characteristic of compressive median neuropathy at the carpal tunnel of the wrist. Compressive median neuropathy is a structural, largely hereditary condition that is usually measurable in both wrists. Most cases of median neuropathy at the carpal tunnel are idiopathic, meaning there is no known cause. Other causes of median nerve compression at the carpal tunnel include bleeding, swelling, and deformity associated with a wrist fracture. Carpal tunnel syndrome can also occur with rheumatoid arthritis, due to the enlarged synovial lining of the tendons causing median nerve compression. The main symptoms are numbness and tingling of the thumb, index finger, middle finger, and the thumb side of the ring finger, as well as pain in the hand and fingers. Symptoms are typically most troublesome at night. Many people sleep with their wrists bent, and the ensuing symptoms may lead to awakening. People wake less often at night if they wear a wrist splint. Untreated, and over years to decades, CTS causes loss of sensitivity, weakness, and shrinkage (atrophy) of the thenar muscles at the base of the thumb. Work-related factors such as vibration, wrist extension or flexion, hand force, and repetitive strain are risk factors for CTS. Other risk factors include being female, obesity, diabetes, rheumatoid arthritis, thyroid disease, and genetics. Diagnosis can be made with a high probability based on characteristic symptoms and signs. It can also be measured with electrodiagnostic tests.
== Organic heterocycles and polymers == Radical cations figure prominently in the chemistry and properties of conducting polymers. Such polymers are formed by the oxidation of heterocycles to give radical cations, which condense with the parent heterocycle. For example, polypyrrole is prepared by oxidation of pyrrole using ferric chloride in methanol:
These towns will be developed in two phases; phase one includes seven townships, while the remaining eleven townships will be developed in phase two. The new towns will encompass essential facilities including schools, Industrial Training Institutes (ITIs), skill development centers, institutes providing technical education and amp, higher education, hospitals, police stations, playgrounds, open spaces, parks, and sports complexes. The new townships will be easily accessible from main roads, feeder roads, national or state highways intersecting the Samruddhi Expressway through the public transport system. The MSRDC adopted land pooling model for land acquisition, wherein 30 percent of the total land acquired under 'Krushi Samruddhi Kendra' program will be returned to landowners. The farmers will also receive compensation of Rs 50,000 per hectare for non-irrigated land and Rs 1 lakh every year for irrigated land for the next 10 years. Based on the suggestions from Wildlife Institute of India (WII), wildlife mitigation measures are planned and necessary structures like cattle underpasses are being built for uninterrupted wildlife movement. Around 320 private communicators were trained and deployed by MSRDC for land acquisition negotiations with prospecting landowners.
Sources: en.wikipedia.org
The Dutch sprinter Foekje Dillema was expelled from the 1950 national team after she refused a mandatory sex test in July 1950; later investigations revealed a Y-chromosome in her body cells, and the analysis showed that she was probably a 46,XX/46,XY mosaic female. In 1953, a human chimera was reported in the British Medical Journal. A woman was found to have blood containing two different blood types. Apparently this resulted from her twin brother's cells living in her body. A 1996 study found that such blood group chimerism is not rare. In 2002, an article in the New England Journal of Medicine described a woman, later identified as Karen Keegan, in whom tetragametic chimerism was unexpectedly identified after she underwent preparations for kidney transplant. Those preparations for the transplant required the patient and her immediate family to undergo histocompatibility testing, the result of which had suggested that she was not the biological mother of two of her three children. In 2002, Lydia Fairchild was denied public assistance in Washington state when DNA evidence appeared to show that she was not the mother of her children. A lawyer for the prosecution heard of the case of Karen Keegan in New England, and suggested the possibility to the defense, who were able to show that Fairchild, too, was a chimera with two sets of DNA, and that one of those sets could have produced the children. In 2009, singer Taylor Muhl's large torso birthmark was diagnosed as resulting from chimerism.
== Scientific publications == Life Length has published to date the following articles: In addition, numerous clients of Life Length have published articles based on the results for work performed by the company demonstrating the uniqueness of the TAT® and related technologies:
== K == Kabachnik–Fields reaction Kharasch–Sosnovsky reaction Keck asymmetric allylation Ketimine Mannich reaction Ketone halogenation Kiliani–Fischer synthesis Kindler reaction Kishner cyclopropane synthesis Knoevenagel condensation Knorr pyrazole synthesis Knorr pyrrole synthesis Knorr quinoline synthesis Koch–Haaf reaction Kochi reaction Koenigs–Knorr reaction Kolbe electrolysis Kolbe nitrile synthesis Kolbe–Schmitt reaction Kornblum oxidation Kornblum–DeLaMare rearrangement Kostanecki acylation Kowalski ester homologation Krapcho decarboxylation Krische allylation Kröhnke aldehyde synthesis Kröhnke oxidation Kröhnke pyridine synthesis Kucherov reaction Kuhn–Winterstein reaction Kulinkovich reaction Kumada coupling
=== Leucomatous corneal opacity (leucoma simplex) === Leucomatous corneal opacity is a dense white opacity which results due to scarring of more than half of the stroma. A number of different presentations of leucomatous corneal opacity exist:
Low-dose naltrexone (LDN) refers to daily naltrexone dosages that are roughly one-tenth or less of the standard opioid addiction treatment dosage. Most published research suggests a daily dosage of 4.5 mg, but this can vary by a few milligrams. LDN has been studied for the treatment of multiple chronic pain conditions, including fibromyalgia, multiple sclerosis, Crohn's disease, long COVID, and complex regional pain syndrome. Naltrexone is approved by the Food and Drug Administration (FDA) for medication-assisted treatment of alcoholism and opioid use disorder (OUD). Bernard Bihari's initial off-label usage of naltrexone in doses ranging from 1.5 mg to 3 mg as an adjuvant therapy for acquired immune deficiency syndrome (AIDS) in the 1980s led to the introduction of LDN into clinical practice. Due to a lack of large-scale clinical trials and standardized research aimed at determining appropriate indications for LDN, it has remained an off-label option.
Sources: en.wikipedia.org
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.
Administered growth hormone supplies the hormone directly, while this peptide acts upstream by prompting the pituitary to release it. The indirect route preserves pulsatile secretion and some endogenous feedback, which changes the hormone and IGF-1 profile observed after treatment.
Reductions in visceral adipose tissue appear consistently in randomized trials of the approved population. Effects on peripheral fat, cardiovascular outcomes, and use outside that population are less well established.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.